Chronic cough, defined as a cough persisting for over eight weeks, poses a significant challenge to healthcare providers due to its multifactorial etiology and complexity in management. This article provides a comprehensive approach to managing chronic cough in clinical practice.
Understanding the pathophysiology of chronic cough is pivotal in its management. The cough reflex is a protective mechanism primarily involving the upper and lower airways, the cough center in the brain, and the afferent and efferent nerves. Any irritation or inflammation in this pathway can result in a chronic cough.
Identifying the cause of chronic cough requires a thorough clinical evaluation. Common culprits include gastroesophageal reflux disease (GERD), postnasal drip syndrome, and asthma. However, less common causes like lung cancer, interstitial lung diseases, and ACE inhibitor use should also be considered.
Treatment should be directed towards the underlying cause. For instance, proton pump inhibitors may be beneficial in GERD-associated cough, while inhaled corticosteroids can be useful in asthma-related cough. Non-pharmacological interventions such as lifestyle modifications and cough suppression techniques can also play a significant role.
Despite targeted treatment, some patients continue to have a persistent cough. This may be due to a hypersensitive cough reflex or unaddressed comorbid conditions. Future research should focus on novel therapeutic targets and personalized medicine approaches for these refractory cases.
Managing chronic cough is complex and necessitates a thorough understanding of its pathophysiology, a comprehensive diagnostic evaluation, and individualized treatment plans. By adopting a patient-centered approach and staying abreast with the latest research, clinicians can improve the quality of life for patients suffering from this debilitating condition.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation